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Abstract
Background
Staphylococcus aureus is the most frequent and fatal cause of left-sided infective endocar-
ditis (IE). New treatment strategies are needed to improve the outcome. S. aureus coagu-
lase promotes clot and fibrin formation. We hypothesized that dabigatran, could reduce
valve vegetations and inflammation in S. aureus IE.
Methods
We used a rat model of severe aortic valve S. aureus IE. All infected animals were random-
ized to receive adjunctive dabigatran (10 mg/kg b.i.d., n = 12) or saline (controls, n = 11) in
combination with gentamicin. Valve vegetation size, bacterial load, cytokine, cell integrins
expression and peripheral platelets and neutrophils were assessed 3 days post-infection.
Results
Adjunctive dabigatran treatment significantly reduced valve vegetation size compared to
controls (p< 0.0001). A significant reduction of the bacterial load in aortic valves was seen in
dabigatran group compared to controls (p = 0.02), as well as expression of key pro-inflam-
matory markers keratinocyte-derived chemokine, IL-6, ICAM-1, TIMP-1, L-selectin (p<
0.04). Moreover, the dabigatran group had a 2.5-fold increase of circulating platelets com-
pared to controls and a higher expression of functional and activated platelets (CD62p+)
unbound to neutrophils.
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Conclusion
Adjunctive dabigatran reduced the vegetation size, bacterial load, and inflammation in
experimental S. aureus IE.
Introduction
Staphylococcus aureus is the most frequent cause of infectious endocarditis (IE) [1] and is associ-
ated with serious clinical manifestations and fatal course in two out of five patients [2] despite
appropriate antibiotic therapy, appropriate management of sepsis and intensive care treatment
often combined with cardiac valve surgery. New therapeutic targets enhancing bacterial clear-
ance and dampening the adverse host responses caused by S. aureus in IE are needed.
The valve vegetation in IE consist of a meshwork of endothelial cells, platelets, fibrin and
embedded bacteria [3]. The interactions between host cells and S. aureus play a pivotal role in
the pathogenesis of IE [4], where platelets, leukocytes and endothelial cells modulate the hemo-
static activity in response to microorganisms [5,6]. S. aureus and thrombin are the most potent
triggers of platelet activation [7–9] facilitating platelet aggregation, degranulation, release of
platelet microbiocidal proteins, adhesive integrins, clotting factors and the release of chemo-
tactic cytokines recruiting neutrophils to the site of infection [10].
Platelets are known for the ability to trigger neutrophil degranulation, referred to as neutro-
phil extracellular traps (NETs) [6,11–13]. This fundamental innate immune effector function
of neutrophils [14] is essential in endovascular infections, but may cause tissue injury [15,16]
and promote additional intravascular thrombosis [17–19]. Furthermore, NETs can promote
thrombin generation both by platelet-dependent and -independent mechanisms [20] and con-
sequently trigger an exaggerated host response and enhancement of biofilm formation [21].
Coagulase is a key virulence mechanism in S. aureus IE [22,23] facilitating the establishment
and clot formation on cardiac valves resulting in a compromised host response and affecting
the efficacy of antibiotics. This common feature of S. aureus secreting coagulase enhances the
progression of valve vegetations and platelet aggregation, which could be a key intervention
target disabling the excessive clot formation induced by S. aureus. Recent studies have shown
anti-virulent effect by targeting coagulase in S. aureus by preventing the complex formation of
coagulase-prothrombin complex (staphylothrombin) and thereby inhibits the subsequent
facilitated fibrin formation [22,24,25]. Another study has shown beneficial effect of combina-
tion of dabigatran and anti-clumping factor in the survival of septic mice [26]. Furthermore,
dabigatran was shown to be effective as prophylactic treatment in a low-grade S. aureus
induced model of experimental IE [27].
Dabigatran is a direct thrombin inhibitor (Factor IIa), blocking the conversion of soluble
fibrinogen to insoluble fibrin. Direct thrombin inhibitors seem to be a promising adjunctive
strategy against intravascular infection caused by S. aureus. However, no studies have evalu-
ated dabigatran as a therapeutic strategy in already established and severe S. aureus IE.
We hypothesized that limiting the process of platelet aggregation and fibrin formation
involved in S. aureus infections by dabigatran treatment might be an effective adjunctive ther-
apy in endocarditis. Our previously developed rat model of aortic valve IE was used [28,29].
Material and methods
Expanded versions of the Methods are presented in the Supplemental material (S1 File).
Dabigatran treatment in S. aureus endocarditis
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Bacterial challenge and growth conditions
S. aureus (NCTC 8325–4), a laboratory derivative (cured of prophages) of the WT sepsis isolate
8325 was used in the present study [30]. The isolate originates from a patient with S. aureus IE
and expresses key virulence factors involved in IE including coagulase, clumping factors, α
and β-hemolysin, protein A. Bacteria were prepared as previously described [28,29].
Dabigatran treatment
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim, Basel, Switzerland) tablets of 75 mg were
dissolved in 9 mL 0.9% saline overnight at 37˚C on shaking table (150 rpm) and doses of 10
mg/kg in 300 μL syringe were administrated intraperitoneal (i.p.). Control rats received i.p.
injections with 300 μL 0.9% saline.
Study animals
Experimental endocarditis model. High-grade aortic valve catheter induced mechanical
lesions were produced in male Wistar rats, weight 225-250g (Janvier Labs, Rennes, France), as
previously described [28,29]. Twenty-four hours after induction of the valve lesion rats were
inoculated by intravenous injection by 0.5 x 107 CFU of S. aureus in a tail vein. Catheters were
removed immediately before inoculation of the bacteria simulating native valve endocarditis
conditions. Sterile thrombotic endocarditis was produced in sham control rats by catheter
induced mechanical lesions without injection of bacteria, as previously described [28,29].
Before catheter procedure all animals were anaesthetised with a mixture of Hypnorm (fentanyl
0.315 mg/mL and fluanisone 10 mg/mL), sterile water and midazolam (5 mg/mL) in 1:2:1 dilu-
tion. Postoperative all rats received buprenorphine s.c. (0.05 mg/kg) every 8h for 48h post pro-
cedure. All rats were maintained in specific-pathogen-free conditions, monitored at least 3
times per day and had free access to water and food ad libitum. Rats reaching an endpoint, suf-
fering or distress were sacrificed with pentobarbital/lidocaine i.p..
Intervention groups. All rats with IE were treated with gentamicin 20 mg/kg/day (Hex-
amycin i.v. solution, Sandoz A/S, Denmark) subcutaneously (s.c.) initiated one day post-infec-
tion (DPI) [28,29]. Rats treated with adjunctive dabigatran etexilate received a dose of 10 mg/
kg in 300 μL saline solution i.p. at 12 h intervals (b.i.d).
Infected rats with severe S. aureus IE were randomized into two intervention groups: 1)
intervention receiving adjunctive dabigatran (10 mg/kg b.i.d.) and gentamicin (20 mg/kg/day)
(dabigatran group, n = 12) and 2) intervention receiving saline and gentamicin (saline group,
n = 11). Rats with catheter-induced valve lesions, but without inoculation of bacteria devel-
oped sterile thrombotic endocarditis. These rats were randomized into: 1) sham controls
receiving dabigatran (n = 6) or 2) sham controls receiving saline only (n = 6). The sham con-
trol group received the same dose of dabigatran as used for infected rats. All rats were evalu-
ated three days after bacterial inoculation (infected rats) or removal of catheter producing
sterile thrombotic endocarditis (sham controls). Intervention groups received two days treat-
ment before evaluation.
Quantitative bacteriology. Was performed as previously described [28].
Digital planimetry. All infected (n = 23) rats and sham controls (n = 12) rats were autop-
sied immediately after lethal i.p. injection of pentobarbital/lidocaine (1 mL of 200/20 mg/mL)
and hearts were aseptically dissected for photographic imaging (Sony Cyber-shot
DSC-RX100) of the aortic valves. Valve vegetation size (mm2) was measured by digital photo-
planimetry (ImageJ, v. 1.49m) by a pathologist blinded to treatment regimens.
Histopathology. See supplemental material (S1 File).
Dabigatran treatment in S. aureus endocarditis
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Flow cytometry and ROTEM analysis
Measurements of platelets, leukocytes and platelet-neutrophil complexes (PNC).
Reagents. The following fluorescence-labelled antibodies were used to separate panels. Panel
1 (neutrophil panel) activated neutrophils CD11b (APC, BD Bioscience, San Jose, CA, US,
562102) and rat granulocytes HIS48 (FITC, BD, 554907). Panel 2 (neutrophil-platelets com-
plexes); resting platelets CD42d (glycoprotein V) (PerCP/Cy5.5, Nordic Biosite, Copenhagen,
Denmark, 148508), activated platelets P-selectin (CD62p) (APC, Nordic Biosite, 148304) and
HIS48 (FITC, BD, 554907).
For sample preparation and flow cytometer settings. See Supplemental material
(S1 File).
ROTEM analysis. Fresh frozen plasma samples (-80 ˚C) were used for rotational throm-
boelastometry (ROTEM) analysis on ROTEM delta (Tem Systems Inc., Munich, Germany)
(S1 File).
Pharmacokinetics of dabigatran. Fourteen healthy rats were used for evaluation of phar-
macokinetics (PK) in rats injected i.p. with single dose dabigatran (10 mg/kg) (Pradaxa, Boeh-
ringer Ingelheim, Basel, Switzerland).
Measurement of cytokine and cell integrins. A 9-plex magnetic beads assay (Bio-Rad, Her-
cules, CA, US) was used to measure the production of granulocyte–colony-stimulating factor
(G-CSF), keratinocyte-derived chemokine (KC, rat analogue to human IL-8), interferon
(IFN)-γ, interleukin (IL)-1β, IL-6, IL-10, IL-17A, vascular endothelial growth factor (VEGF),
RANTES, (CCL5) (S1 File).
Ethics statement
All animal experiments were approved by The Animal Ethics Council and The Animal Experi-
ments Inspectorate in Denmark (License no. 2013-15-2934-00952). Animal experiments were
conducted according to institutional guidelines at Copenhagen University at Department of
Experimental Medicine (accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC) since 2009), Danish laws and regulations
and EU Directives and Conventions (https://emed.ku.dk/about/policies/).
Statistical analysis
All calculations were performed using GraphPad Prism (version 7.2, GraphPad Software, Inc.,
San Diego, USA). Bacterial tissue densities, cytokines and adhesins were transformed logarith-
mically (log10) and expressed by mean ± standard deviation (SD). Quantitative bacteriology
and cytokines were verified by normality test for parametric data and pairwise comparison
with Student’s unpaired t-test. For multiple comparisons, one-way and two-way ANOVA
Tukey´s multiple comparisons test was applied. Categorical data were analyzed by Chi-square.
Flow cytometry were analyzed and calculated with BD FACS Diva software (v.6) and Flow Jo
(v. 10). P� 0.05 was considered significant.
Results
Pharmacokinetics of dabigatran
Dabigatran peak plasma concentrations (Cmax, ~800 μg/L) were reached within one-hour post
injection of the prodrug, indicating rapid absorption and conversion to active dabigatran.
Dabigatran trough plasma concentration was measured after 5 hours (Cmin, 40 μg/L). There
was no measurable residual dabigatran in the plasma after 12 hours (Fig 1).
Dabigatran treatment in S. aureus endocarditis
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Effect of dabigatran on valve vegetation size
The aortic valve vegetations were significantly reduced in size in dabigatran compared to saline
treated animals (1.6 ± 0.9 vs 3.8 ± 1.3 mm2, p< 0.0001) (Fig 2A). A similar difference was
seen in uninfected sham controls receiving dabigatran vs. saline (1.1 ± 0.6 vs. 2.8 ± 1.7 mm2,
p = 0.04) (Fig 2A). Representative macroscopic images of valve vegetations from dabigatran
and saline treated group are illustrated in Fig 2B and 2C, respectively.
Effects of dabigatran on the bacterial load in infected valves
A significant reduction of ~1 log colony-forming units (CFU) was seen in the valve vegetations
in the group receiving dabigatran compared to the group receiving saline (7.01 ± 1.4, n = 12 vs.
8.03 ± 0.8, n = 11, p = 0.02) (Fig 3A).
Effect of dabigatran on the bacterial load in myocardium, spleen, and blood
Similar reductions were seen in myocardium (5.58 ± 1.3 vs. 6.66 ± 1.0, p = 0.04) (Fig 3B) and
spleen (3.78 ± 1.4 vs. 5.24 ± 6.2, p = 0.02) (Fig 3C) comparing the two intervention groups.
Rats receiving dabigatran treatment had 50% negative blood cultures compared to 9% in the
saline group (p = 0.03) (Fig 3D). In kidneys, tissue negative cultures were seen in 33% (4/12)
of dabigatran treated compared to 9% (1/11) in the saline group (p = 0.31) (data not shown).
All the uninfected sham controls were culture negative from blood and aortic valves.
Two animals perished during the treatment course and were excluded from the evaluation.
One, in the dabigatran group, due to peritoneal fecal co-infection (possible cage acquired
infection) and the other in the saline group due to severe progression of IE with intracerebral
affection with limb paresis.
Fig 1. Dabigatran pharmacokinetics (PK). PK of dabigatran etexilate administrated by one dose of 10 mg/kg
intraperitoneal. Plasma dabigatran (p-dabigatran) were measured in two healthy rats at each time point (n = 14). A
peak p-dabigatran concentration was seen after 1 hour (~800 μg/L) and though value was seen at 5 hours (40 μg/L).
https://doi.org/10.1371/journal.pone.0215333.g001
Dabigatran treatment in S. aureus endocarditis
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Effect of dabigatran on cytokine and integrin levels in affected valves
All cytokine and adhesin markers were elevated in rats with IE compared to rats with sterile
thrombotic endocarditis, indicating a highly mobilized and active host response in valves
Fig 2. Dabigatran effect on valve vegetation size. A significant reduction in valve vegetation size was seen for
dabigatran treated (10 mg/kg/b.i.d) compared to saline treated rats with S. aureus infective endocarditis (infected)
evaluated 3 days post inoculation (Fig 2A). Both infected groups received gentamicin 20 mg/kg/day (s.c.). A significant
reduction of the valve vegetation size was seen in sham control (uninfected) with sterile thrombotic endocarditis in the
dabigatran treated (10 mg/kg/b.i.d) group compared to saline controls evaluated 3 days post removal of catheter (Fig
2A). Representative macroscopic images of valve vegetations from one rat treated by dabigatran (Fig 2A) and saline
(Fig 2C), arrows indicating the valve vegetations located at the aortic leaflets. Black scale bar indicates 3 mm.
Horizontal lines represent means ± standard derivation. � indicate p< 0.05 by unpaired t-test.
https://doi.org/10.1371/journal.pone.0215333.g002
Dabigatran treatment in S. aureus endocarditis
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colonized with S. aureus (S1 Table). Keratinocyte-derived chemokine (KC) (analogue to
human IL-8) is the most sensitive marker for inflammation in valve tissue of IE, followed by
IL-6 and IL-1β [28]. An almost 2-fold reduction of KC (Fig 4A) and IL-6 (Fig 4B) were seen in
the dabigatran compared to the saline group (594 ± 523 vs. 1057 ± 590 pg/mL, p< 0.01 and
137 ± 155 vs. 269 ± 259 pg/mL, p< 0.05, respectively). IL-1β showed a non-statistical signifi-
cant 1.4-fold reduction in the dabigatran treated group (p = 0.09) and RANTES 1.4-fold
increase (p = 0.09) (S1 Table). Ratio between pro-inflammatory and anti-inflammatory
expression by KC and IL-10, KC and RANTES showed significant reduction in the dabigatran
group compared to the saline group (p = 0.03 and p = 0.02, respectively). A significant reduc-
tion of RANTES were seen in sham controls receiving dabigatran compared to saline treated
sham controls (p< 0.03) (S1 Table).
Important cell surface adhesins and glycoproteins expressed by platelets, leukocytes and
endothelial cells were quantified showing significant reduction of L-selectin and ICAM-1 in
the dabigatran treated compared to saline treated (5802 ± 3215 vs. 8189 ± 2443 pg/mL and
3518 ± 1808 vs. 8189 ± 2443 pg/mL, p< 0.04, respectively) (Fig 4C and 4D). Interestingly, tis-
sue metallopeptidase inhibitor 1 (TIMP-1) expressed by endothelial cells and platelets, an
Fig 3. Dabigatran effect on bacterial load. A significant reduction in the bacterial load were seen in valves (A), myocardium (B) and spleen (C) in dabigatran
(10 mg/kg/b.i.d) compared to saline treated group. A significant reduction of positive blood cultures in the dabigatran compared to saline group (D) was seen.
Horizontal lines represent means ± standard derivation. � indicate p< 0.05 by unpaired t-test (A-C) and chi-square test (D).
https://doi.org/10.1371/journal.pone.0215333.g003
Dabigatran treatment in S. aureus endocarditis
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important reactivity marker for these cells, revealed a significant reduction in the dabigatran
treated compared to saline treated rats (8095 ± 11186 vs. 14619 ± 9026, p< 0.02) (S1 Table).
Importantly, uninfected sham controls were observed to have a significant reduction of P-
selectin in dabigatran treated compared to saline treated, indicating reduced platelet aggrega-
tion in valves (489 ± 642 vs. 2686 ± 548 pg/mL, p< 0.0001) (S1 Table), however for infected
rats only a non-significant reduction in P-selectin was seen in dabigatran treated compared to
saline treated group (S1 Table).
No difference was seen between the two uninfected dabigatran or saline treated sham con-
trol groups. Concerning von Willebrand factor (vWF), thrombin-antithrombin complexes
(TAT) and tissue factor (TF) no differences was found between the two intervention groups.
Fig 4. Dabigatran effect on cytokines and integrins in valves. A significant reduction in key inflammatory markers as keratinocyte-derived
chemokine (rodent homolog to human interleukin 8 (IL-8)) (A), IL-6 (B), L-selectin (C), ICAM (D), in infected rats was seen in dabigatran
compared to saline treated.
https://doi.org/10.1371/journal.pone.0215333.g004
Dabigatran treatment in S. aureus endocarditis
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However, TAT was significantly increased in dabigatran treated sham compared to saline
sham controls (p = 0.05) (S1 Table).
Neutrophils, platelets and platelet-neutrophil-complex in S. aureus IE
To investigate the interaction between platelets and neutrophils in the circulation during IE,
we measured the complex binding between platelets and neutrophils. Platelet-neutrophil com-
plex formation was high in both intervention groups (mean fluorescence index (MFI) ~4200),
but no difference was observed (S2A Fig).
Interestingly however, the infected group receiving adjunctive dabigatran had a significant
2.5-fold increase of circulating platelets unbound to leukocytes compared to the saline group
(mean of 4.0 vs. 1.6 x 108 platelets/L, respectively), indicating a higher turnover of platelets in
the latter group (Fig 5A). Moreover, the number of activated platelets (expressing CD62p)
unbound to leukocytes was significantly higher in the dabigatran vs. saline group (MFI,
21569 ± 14315 vs MFI 8576 ± 4926, p = 0.04), indicating a higher number of functional and
activated platelets in the circulation (Fig 5B).
Neutrophils and total leukocyte count (TLC) measured by flow cytometry revealed a statis-
tical non-significant reduction in the dabigatran treated group of neutrophils (mean 4.39 vs
8.77 x 109 neutrophils/L, p = 0.20) and TLC (mean 7.11 x 108 vs. 1.25 x 109 TLC/L, p = 0.18)
respectively (S3B and S3C Fig).
Rotational thromboelastometry (ROTEM) analysis in rats with S. aureus IE
No significant difference was found between the two infected intervention groups in regard to
clotting time (CT), clot formation time (CFT), alpha angle or maximum clot formation
(MCF). Showing comparable hemostatic functionality of the intrinsic and extrinsic pathways,
no increased bleeding time was observed in either groups (S2 Table).
Histopathologic characteristics of tissue specific inflammation in S. aureus IE
For results see S3 Table and illustrative figures (S1 and S2 Figs) in supplemental material.
Interaction between S. aureus and dabigatran in a plasma assay
See supplemental material (S4 Fig).
Discussion
In the present study of experimental aortic valve S. aureus IE, we demonstrated that adjunctive
dabigatran therapy combined with gentamicin reduces the valve vegetation size, bacterial load
on the valves, in the myocardium, spleen and fewer persistently positive blood cultures of dabi-
gatran treated rats.
Furthermore, dabigatran reduced the key pro-inflammatory cytokines KC (IL-8), IL-6 and
IL-1β [28,29], cell integrins and metalloproteases L-selectin, ICAM-1 and TIMP-1 in valve veg-
etations. The levels of IL-8, IL-6 and IL-1β is primarily released by activated platelets, indicat-
ing reduced platelet aggregation and neutrophil shedding of L-selectin upon activation,
tethering and adhesion [31] of the inflamed endothelium. The reduced TIMP-1 expression
correlated to the reactivity and number of platelets within the vegetation [32]. P-selectin was
significantly reduced in uninfected sham controls receiving dabigatran compared to saline
sham controls, indicating reduced aggregation of platelets in sterile thrombotic vegetations.
However, this effect could not be identified in the infected rats, probably due to the severe
inflammation and high bacterial burden of both groups at the time of evaluation.
Dabigatran treatment in S. aureus endocarditis
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Interestingly, RANTES levels were elevated in infected valves and inversely correlated to
pro-inflammatory cytokines, showing a decreased ratio score of KC/RANTES (pro-inflamma-
tory/anti-inflammatory) in the dabigatran treated group compared to the saline treated group
(p<0.02). This observation may be indicative of the recruitment of monocytes (removing
debris and promoting tissue healing), increased monocyte-platelet crosstalk stimulating anti-
inflammatory signals (e.g. IL-10 production) [33] and signaling toward an earlier activation of
the adaptive immune response [34]. This speculation is supported by the fact that the
Fig 5. Flow cytometric analysis of platelets. Platelets count (A), unbound activated platelets expressed by mean
fluorescence index (MFI) (CD62p+) (B), Horizontal lines represent means ± standard derivation. � indicate p< 0.05.
https://doi.org/10.1371/journal.pone.0215333.g005
Dabigatran treatment in S. aureus endocarditis
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observation adheres to the infection and not the sterile vegetations since the RANTES level is
comparable to the background level of healthy controls. The anti-inflammatory effect of dabi-
gatran was also seen by reduced ratio score of KC/IL-10.
Between the two intervention groups there were no difference in platelet-neutrophil com-
plexes. Although, this is in accordance with observations in a sepsis model of streptococci [35],
we observed significant difference in the platelet turnover between the two groups, where the
dabigatran treated group had a higher platelet count and a higher number of functional acti-
vated platelets compared to saline treated. Reduction in platelets is a well-known biomarker
for disease severity and our observations highlight the anti-virulent effect of dabigatran in our
S. aureus IE model. Patients with bacteremia has a high number of platelet-leukocyte com-
plexes compared to healthy controls. However, in patients with complicated sepsis with organ
failure, the number of platelet-leukocyte complexes has shown to be decreased, probably a
consequence of a high turnover of platelets sequestrating as micro-thrombosis causing organ
ischemia, tissue and vessel damage [36].
Various disease models and in vitro studies have shown the important aspect between plate-
lets and neutrophils in intravascular infections. Platelets, neutrophils and the formation of
complexes between the two is an important effector function of the innate immunity in the
battle against S. aureus in endovascular infections. However, cross-talk between the coagula-
tion system and innate immunity promotes coagulation [4,37], induces biofilm formation in
IE [21] and upregulates the pro-inflammatory cytokine production [28,29,38] for recruitment
of neutrophils promoting additional inflammation by degranulation (NET release) in the
valves [39,40].
Dabigatran shows promising signs in a potential strategy to dampen the exaggerated host
response between platelets and neutrophils triggered by S. aureus. In vitro, it has been shown
that dabigatran in high concentrations can reduce platelet activation, and in low concentra-
tions inhibit thrombin induced platelet aggregation [41] with combined stimulation by platelet
agonists. Another way of attenuating bacteria-induced inflammation has been demonstrated
in whole blood models [42], however in such a setting, it is important to recognize the direct
anti-virulent effect of direct thrombin inhibitors towards S. aureus.
Furthermore, dabigatran has shown to promote the fibrinolytic activity altering the clot
structure [43], which might contribute to reduced resistance against the host response and
antimicrobial agents. Dabigatran could have similar effects, as shown by treatment with
recombinant protein A2 (fragment of vWF) in lipopolysaccharide-induced DIC murine
model, by reducing fibrin-rich microthrombi dissemination [44].
The hemostatic function and clot formation time were comparable between the two inter-
vention groups, indicating no accumulation of dabigatran and no excess coagulation times of
dabigatran treated rats, although we observed high peak concentration in healthy controls
with the chosen treatment dose. Coagulopathy in sepsis and IE is a dynamic process; sequential
measurements are needed to evaluate the in vivo effect of dabigatran in S. aureus IE, although
beyond the scope of this study.
To assess the safety of adjunctive dabigatran, tissue samples were evaluated by histopathol-
ogy. Importantly no increased hemorrhagic tissue damage in the myocardium, spleen and kid-
ney was observed in dabigatran treated. Furthermore, a trend toward decreased inflammation
and kidney necrosis of dabigatran treated was observed, which may be explained by reduced
microthrombi sequestering in the kidneys. No additional inflammatory differences were seen
between the intervention groups, but this could probably be explained by the low number of
animals in the assessment.
Our blood cultures findings are in correlation with the first prospective randomized study
comparing dabigatran treatment to standard thromboprophylaxis of patients with S. aureus
Dabigatran treatment in S. aureus endocarditis
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bacteremia [45], which showed acceptable and similar rates of bleeding events in 94 enrolled
patients. The study [45] also observed a trend of less persistently blood cultures in dabigatran
treated patients as we observed in our study, indicating augmented effects of gentamicin and
the host response.
Coagulase activity is expressed in all S. aureus making this pathogen specific target a poten-
tial strategy, as presented in this study, by blocking the formation of staphylothrombin com-
plexes [24,45]. This direct effect is likely not applicable for other pathogens, but future studies
will need to clarify the role of dabigatran in Gram-positive bacteria e.g. streptococcal and
enterococcal IE.
Multiple preclinical studies of IE have shown the benefit of antiplatelet therapy [46,47] and
combination of ticlopidine and aspirin to prevent IE in S. aureus and Streptococcus gordonii
[27]. Furthermore, dabigatran was protective in 75% of rats infected by S. aureus, however
failed to be protective against S. gordonii [27], highlighting dabigatran direct effect toward S.
aureus also demonstrated in our study. The benefit of therapeutic anticoagulation in native IE
has never been demonstrated efficient in a clinical setting. Current guidelines from ESC [48]
and American Heart Association [49] does not recommend anticoagulation, but we lack well-
designed clinical randomized studies in IE to out rule the use of anticoagulant therapy in
native endocarditis.
The present study is first proof-of-concept of dabigatran as beneficial adjuvant treatment of
established severe S. aureus aortic valve endocarditis. Our study illustrates that by targeting
platelet activation pathways, we can reduce the platelet and neutrophil induced inflammation
and biofilm formation on cardiac valves promoted by S. aureus. Left-sided endocarditis with S.
aureus is an infectious disease with an unchanged and undesirable high frequency of severe
complications and fatality rate. Therefore, new treatment options to improve the outcome are
needed. Such new treatment strategies are extremely challenging to develop and test directly in
clinical randomized trials of IE, currently with only two IE studies performed [50,51].
The present rat model of severe left-sided aortic S. aureus endocarditis is suitable for pre-
clinical research on potential beneficial treatments of patients with IE [28,29]. In our model,
we mimic the cause of progressive S. aureus IE and hypothesized improvement of dabigatran
as adjunctive treatment in the early management of S. aureus IE.
In conclusion, the present study demonstrates that dabigatran augments the antibiotic effi-
cacy by reducing the valve vegetation size, platelet aggregation, bacterial load, inflammation,
and dissemination in an experimental model of native S. aureus aortic valve endocarditis.
Supporting information
S1 Fig. Histopathological representative illustrations of catheter induced Staphylococcus
aureus (S. aureus) infective endocarditis (IE). (A) Valve vegetation of severe S. aureus IE by
hematoxylin and eosin stain (H&E) (Magnification x10). (B) fibrin (red) sequestering S.
aureus in valve vegetations (x10) Martius Scarlet Blue (MSB). C) illustrating aortic root abscess
in myocardium (x2.5) with (D) severe neutrophil inflammation and inflamed valve (x20). e)
spleen with hyperplasia of white pulp with (x20) (F) CD61 positive megakaryocytes (x20) (G)
showing two large areas of necrosis in the renal cortex, one at each pole of the kidney, the big-
gest marked by a dark square (overview), (H) enlarged picture of the area marked by the dark
square in picture (G) showing the characteristic infarction with tissue necrosis in the kidney
(x2.5).
(TIF)
S2 Fig. Histopathological illustrations from rats in the saline group. (A) Severe neutrophil
infiltration of the aortic valve and subendothelial (hematoxylin and eosin (H&E), magnification
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x20) and (B) counterstained with Martius Scarlet Blue (MSB) where the collagen is strongly
blue but no stains for fresh (yellow) or mature (red) fibrin. (C) Inflamed spleen (H&E, magnifi-
cation x40) and (D) counterstained with myeloperoxidase (MPO), magnification x40) display-
ing a high intracellular expression of MPO in the neutrophils.
(TIF)
S3 Fig. Flow cytometry of whole blood. Platelet-neutrophil complexes (PNC) (A), neutro-
phils (B) and total leukocyte count (TLC) (C) are shown for the two intervention groups. Hor-
izontal lines represent means ± standard derivation. � indicate p< 0.05. n.s., non-significant.
(TIF)
S4 Fig. Dabigatran inhibits growth of S. aureus in plasma. Growth curve of S. aureus incu-
bated in plasma from rats at different dabigatran concentrations (25–730 μg/L) showing a
delayed growth rate of S. aureus at high plasma dabigatran concentrations (544 and 730 μg/L),
indicating a direct anti-S. aureus effect of dabigatran in plasma. P< 0.0001 at plasma dabiga-
tran concentrations at 730 and 544 μg/L from 1–8 hours compared to< 25 μg/L plasma dabi-
gatran. Experiments were performed in duplicates. Symbols and error bars indicating
mean ± SEM.
(TIF)
S1 Table. Cytokines and adhesion molecules expression in aortic valve endocarditis.
(DOCX)
S2 Table. Results of ROTEM performed in plasma samples.
(DOCX)
S3 Table. Histopathological assessment.
(DOCX)
S1 File. Extended Material, Method and Results section.
(PDF)
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